# US 2022/0267260 A1 · Compounds containing a sulfonic group as kat inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0267260 A1
- Document ID: US20220267260A1
- Status: Published application
- Kind: A1
- Application number: 16/464,584
- Filed: 2017-11-29
- Published: 2022-08-25
- Earliest claimed: 2016-11-29
- Assignees: Epizyme, Inc.
- Applicants: Epizyme, Inc.
- Inventors: Darren Martin Harvey
- Web page: https://patentgrep.com/patent/US20220267260A1

## CPC

- C07C 311/49: to nitrogen atoms
- A61P 35/00: Antineoplastic agents
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D 207/36: Oxygen or sulfur atoms
- C07D 207/48: Sulfur atoms
- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/24: by sulfur atoms to which a second hetero atom is attached
- C07D 211/54: Sulfur atoms
- C07D 211/60: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 213/26: Radicals substituted by halogen atoms or nitro radicals
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 231/56: Benzopyrazoles; Hydrogenated benzopyrazoles
- C07D 235/24: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D 239/28: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D 263/28: Nitrogen atoms not forming part of a nitro radical
- C07D 263/50: Benzene-sulfonamido oxazoles
- C07D 265/30: not condensed with other rings
- C07D 275/03: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 305/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
- C07D 307/18: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 309/06: Radicals substituted by oxygen atoms
- C07D 309/08: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 333/48: by oxygen atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 407/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 471/04: Ortho-condensed systems
- C07D 471/10: Spiro-condensed systems
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

## Claims

### Claim 1

A compound of formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Ring A is selected from phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, a 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, an 8-10 membered bicyclic aryl ring, an 8-10 membered bicyclic heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen oxygen and sulfur, and an 8-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen oxygen and sulfur;
L is a 3- to 6-atom linker comprising at least one —S(O)2— group and 1-4 additional groups independently selected from —C(O)—, —NH—, —O—, and C1-3 aliphatic; wherein:
two atoms of L may, together with their intervening atoms, form a 4-6 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, or a 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur;
Ring B is an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, a 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, an 8-10 membered bicyclic aryl ring, and an 8-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen oxygen and sulfur;
Ra is selected from halogen, —CN, —NO2, —OR, —SR, —N(R)2, —C(O)R, —C(O)2R, —OC(O)R, —C(O)N(R)2, —N(R)C(O)R, —Cy, or optionally substituted C1-4 aliphatic;
Z is selected from halogen, —CN, —NO2, —OR, —SR, —N(R)2, —C(O)R, —C(O)2R, —OC(O)R, —C(O)N(R)2, —N(R)C(O)R, —Cy, —(C1-3 aliphatic)-Cy or optionally substituted C1-4 aliphatic;
Cy is an optionally substituted group selected from phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, a 6-8 membered bridged bicyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, a 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, an 8-10 membered bicyclic aryl ring, and an 8-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen oxygen and sulfur;
each R is independently hydrogen or an optionally substituted group selected from C1-4 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, a 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur, an 8-10 membered bicyclic aryl ring, and an 8-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen oxygen and sulfur;
n is 0 or 1; and
x is 0, 1, 2, or 3.

### Claim 2 (depends on 1)

The compound according to claim 1, wherein L is a 3-atom linker.

### Claim 3 (depends on 2)

The compound according to claim 2, wherein L is

### Claim 4 (depends on 1)

The compound according to claim 1, wherein L is a 4-atom linker.

### Claim 5 (depends on 4)

The compound according to claim 4, wherein L is selected from the group consisting of

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The compound according to claim 1, wherein L is a 5-atom linker.

### Claim 8 (depends on 7)

The compound according to claim 7, wherein L is selected from the group consisting of

### Claim 9 (depends on 1)

The compound according to claim 1, wherein Z is optionally substituted C1-4 aliphatic.

### Claim 10

(canceled)

### Claim 11 (depends on 1)

The compound according to claim 1, wherein Z is —Cy.

### Claim at position 12

12-14. (canceled)

### Claim 15 (depends on 1)

The compound according to claim 1, wherein Ring B is an optionally substituted 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur.

### Claim at position 14

16-22. (canceled)

### Claim 23 (depends on 1)

The compound according to claim 1, wherein Ring A is phenyl.

### Claim 24 (depends on 1)

The compound according to claim 1, wherein Ring A is a 8-10 membered bicyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen oxygen and sulfur.

### Claim 25 (depends on 1)

The compound according to claim 1, wherein Ring A is a 3-7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur.

### Claim 26 (depends on 1)

The compound according to claim 1, wherein the compound is selected from formulae I-a, I-b, I-c, I-d, I-e, I-f, I-g, I-h, I-j, I-k, I-l, I-m, I-n, I-o, I-p, I-q, I-r, or I-s:
or a pharmaceutically acceptable salt thereof.

### Claim 27 (depends on 1)

The compound according to claim 1, wherein the compound is selected from a compound of formulae II, III, IV or V:
or a pharmaceutically acceptable salt thereof.

### Claim 28 (depends on 1)

A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 1, and a pharmaceutically acceptable excipient.

### Claim 29 (depends on 1)

A method of treating a disease or disorder associated with KAT-5 in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 1.

### Claim 30 (depends on 1)

A method of modulating protein acetylation in a subject in need thereof, comprising administering to the subject an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 1.

### Claim 31 (depends on 1)

A method of treating cancer in a subject, comprising administering to the subject an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 1.

### Claim 32 (depends on 31)

The method of claim 31, further comprising administering to the subject an additional therapeutic agent.
